Biograil™

About

Biograil™ is a pre-clinical stage pharmaceutical company based in Denmark, founded in 2019. The company focuses on innovative drug delivery technologies that convert injectable biologics into oral capsules, enhancing patient compliance and convenience. Biograil's proprietary BIONDD® technology allows for non-invasive administration of medications, improving the delivery of antibodies, oligonucleotides, peptides, and enzymes. The BIONDD® technology features a patented device that dissolves in the stomach, attaches to the stomach wall, and releases medication directly into tissue, achieving high bioavailability. Biograil holds 12 patents related to dosage forms and drug delivery devices. The company collaborates with pharmaceutical partners, including Eli Lilly and Co. and CSL, to adapt injectable products for oral delivery. With a small team and significant investment backing, Biograil is positioned to make a meaningful impact in the pharmaceutical industry by prioritizing patient-centric oral options.